The US Food and Drug Administration’s Generic Drug Cluster has facilitated the gathering and combining of data in several key indications during its first year in operation, a progress report has revealed.
The group said the discussions it has had over the last year “promoted an understanding of approval basis focusing on a number of generic drug applications of high priority, as well as
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?